Welcome to our dedicated page for Mersana Therapeutics news (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics stock.
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancers with high unmet medical need. Its news flow reflects both scientific progress and corporate developments, making the MRSN news page a focused source for investors and observers following oncology drug development and transaction activity.
Company press releases emphasize updates from its ADC pipeline, particularly Emi-Le (emiltatug ledadotin; XMT-1660), a B7-H4-directed Dolasynthen ADC, and XMT-2056, an Immunosynthen ADC targeting a novel HER2 epitope. News items have covered interim Phase 1 clinical data for Emi-Le in triple-negative breast cancer and adenoid cystic carcinoma type 1, including objective response rates and safety observations, as well as plans for dose expansion cohorts and future data readouts. Additional scientific news includes presentations at major oncology congresses such as ASCO and ESMO Breast Cancer.
Mersana’s news releases also detail collaboration milestones with partners including GSK, Janssen Biotech, Inc. (Johnson & Johnson) and Merck KGaA, Darmstadt, Germany. Examples include the achievement of development milestone payments and FDA clearance of an investigational new drug application for a Dolasynthen ADC developed under a collaboration. Corporate and capital markets news has included announcements of quarterly financial results, a 1-for-25 reverse stock split designed to support Nasdaq listing compliance, and notices related to Nasdaq listing standards.
A significant portion of recent news is devoted to the proposed acquisition of Mersana by Day One Biopharmaceuticals, Inc., including the terms of the tender offer, the structure of the contingent value rights and the expected timing of closing. Readers of the MRSN news page can therefore expect a mix of clinical trial updates, collaboration developments, financial disclosures, listing-related actions and transaction announcements. For ongoing context around these events, this page can be revisited as new company communications are released.
Mersana Therapeutics (NASDAQ:MRSN) reported promising results for its XMT-1536 Phase 1 study in ovarian cancer, showing a 34% objective response rate, including 7% complete responses. The FDA granted Fast Track Designation for XMT-1536, enhancing its potential market entry. The company ended Q3 2020 with $271 million in cash, enabling them to fund operations for over two years. R&D expenses rose to $16.5 million due to increased clinical activities. The net loss was $22.5 million, or $0.33 per share, compared to a loss of $16.8 million, or $0.35 per share, in Q3 2019.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced that CEO Anna Protopapas will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 11 at 11:00 a.m. ET. A live webcast of the presentation can be accessed on Mersana’s website, with an archived replay available for 90 days. Mersana is focused on developing antibody-drug conjugates (ADCs) to address significant cancer treatment needs. Their lead candidate, XMT-1536, is in a Phase 1 clinical study for ovarian cancer, while XMT-1592 targets NaPi2b-expressing tumors.
Mersana Therapeutics (NASDAQ:MRSN) announced a conference call and webcast on November 9, 2020, at 8:00 a.m. ET. The call aims to discuss its third-quarter financial results for the period ending September 30, 2020, and provide business updates. The company is focused on developing antibody-drug conjugates (ADCs) to target cancers with significant unmet needs. Their lead candidate, XMT-1536, is currently in a Phase 1 trial for ovarian cancer and NSCLC adenocarcinoma, while XMT-1592 is in a dose escalation Phase 1 trial targeting NaPi2b-expressing tumors.
Summary not available.
Mersana Therapeutics (NASDAQ: MRSN) reported interim data from a Phase 1 study of XMT-1536 for ovarian cancer, showing a 34% objective response rate and a 79% disease control rate among 47 patients. The drug was well-tolerated, with no new safety signals. Notably, two patients achieved complete responses. The trial targets patients with platinum-resistant cancer and highlights the potential for biomarker-based patient selection. Mersana aims to advance into registration-enabling studies and present more mature results by year-end.
Mersana Therapeutics (NASDAQ:MRSN) announced updated interim data from its ongoing Phase 1 expansion study of XMT-1536, targeting ovarian cancer. The data will be shared in an e-poster at the 2020 ESMO Virtual Congress starting on September 17, 2020. This ADC aims to improve efficacy and safety for patients. Additionally, a conference call featuring study investigator Erika Hamilton, MD will be held on the same day to discuss these findings further, emphasizing the company’s commitment to advancing cancer treatment.
Mersana Therapeutics announced the appointment of Chuck Miller as Senior Vice President of Regulatory Affairs, along with a stock option grant for up to 120,000 shares at $19.16 each, fully vesting over four years. The grant complies with Nasdaq's Inducement Award rules. The company focuses on developing innovative antibody-drug conjugates for cancer treatment, with lead product XMT-1536 in Phase 1 trials for ovarian cancer and NSCLC. Mersana’s pipeline also includes other ADC candidates targeting high unmet medical needs.
Mersana Therapeutics (Nasdaq: MRSN) announced the appointment of Chuck Miller as Senior Vice President of Regulatory Affairs. With over 25 years of experience, Miller has previously held leadership roles at TESARO and Cubist. He was integral in the regulatory approval of significant products like ZEJULA and ZERBAXA. As Mersana focuses on advancing its clinical pipeline, including XMT-1536 for ovarian cancer and XMT-1592, Miller's expertise is expected to be crucial. His appointment aligns with the company’s ongoing commitment to improving outcomes for cancer patients.
Mersana Therapeutics (NASDAQ:MRSN) reported promising interim data from its XMT-1536 Phase 1 study, showcasing a 35% objective response rate in ovarian cancer patients. The company initiated a Phase 1 study for its Dolasynthen ADC, XMT-1592. Financially, Mersana raised $240 million in gross proceeds, providing funding for over two years. Despite a net loss of $19.8 million in Q2 2020, an increase in collaboration revenue to $0.8 million was noted. Mersana plans to further disclose data at ESMO and anticipates updates on its clinical programs.
Mersana Therapeutics, Inc. (NASDAQ: MRSN) announced its participation in two investor conferences in August 2020. The company focuses on developing antibody-drug conjugates (ADCs) to treat cancers with significant unmet medical needs. Key events include:
- BTIG Virtual Biotechnology Conference - August 11, 2020, 1:00 p.m. ET (Fireside Chat)
- Wedbush PacGrow Healthcare Virtual Conference - August 12, 2020, 1:45 p.m. ET (Presentation)
Webcasts will be available on Mersana's website, with archived replays for 90 days.
FAQ
What is the current stock price of Mersana Therapeutics (MRSN)?
What is the market cap of Mersana Therapeutics (MRSN)?
